Best Biopharma Outsourcing Companies in South Korea
The 92 best Biopharma Outsourcing companies in South Korea in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Prestige Biologics.
Ranking the best Biopharma Outsourcing companies in South Korea by disclosed equity funding, this directory tracks 92 firms with a combined $38M raised. That's a lean pool, and Prestige Biologics accounts for nearly all of it at $35M, with Novacell Tech a distant second at $3M. The global market context makes that funding gap worth noting: the [biopharma outsourcing market sits at $28.7B in 2024 and is forecast to reach $112.3B by 2032](https://market.us), a 5.8% CAGR driven by soaring biologics demand and rising drug development costs. So you're looking at a domestic sector that's genuinely early-stage against a global backdrop moving fast.
Hot themes right now are clinical trial outsourcing, viral vector vaccines, and vaccine formulation, which tells you where the next funding rounds are likely to land. Coverage is otherwise flat, meaning the companies building real moats in clinical protocol and biologics manufacturing are running ahead of the capital. I'd watch the investor mix closely here: Aju IB Investment, Korea Investment Holdings, and Hyundai Venture Investment are the most active backers, and their appetite will shape which of these 92 firms graduate from zero-disclosed to the next Prestige Biologics. Regulatory compliance pressure is tightening globally, and that's actually a tailwind for credible Korean CDMOs with GMP track records.
- ResearchAndMarkets.com
- market.us
Our analysis of 100 Biopharma Outsourcing companies
$10.3b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Biopharma Outsourcing companies in South Korea
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Prestige Biologics CDMO focused on manufacturing of biologics and commercialization services | $35M | 39 mo ago | Series C | — | 2015 | — | 33 patents Antibody biomanufacturing: culture, purification, aseptic connections, and AI monitoring systems | 1 partnership |
| 2 | Novacell Tech Manufacturer of small molecules & peptides | $3M | 74 mo ago | Series A | Taehoon Lee CEO | 2000 | — | — | — |
| 3 | Empathy Plus Provider of biopharma outsourcing services | — | 24 mo ago | Seed | Kyungsik Choi CEO | 2022 | — | — | — |
| 4 | BnH Research Provider of drug discovery, consulting, and evaluation services | — | 48 mo ago | Series B | Chung - Founder | 2018 | — | — | — |
| 5 | Naason Science Provider of preclinical studies services | — | 83 mo ago | Funding Raised | Larry Park CEO | 2016 | GoDaddy Website BuilderAmazon ALBAmazon Web Services+10 | — | — |
| 6 | ST PHARM CDMO providing oligonucleotide, mRNA, and small molecule services | — | 126 mo ago | Public | Kyungjin Kim President/Ceo | 2008 | TypeScriptCKEditorThree.js+18 | 312 patents Lipid nanoparticle delivery systems for nucleic acids and pyrrolopyridine kinase inhibitor therapeutics | — |
| 7 | Corestem Biotech specializing in stem cell therapies for treating rare diseases | — | 154 mo ago | Public | Kyung Kim CEO | 2003 | — | 125 patents Patents concentrated in health & consumer products | — |
| 8 | Biotoxtech Provider of preclinical services for evaluating safety and efficacy of new treatments | — | 302 mo ago | Public | Gangjonggu CEO | 2000 | JavaGSAPjQuery | 13 patents Hydroquinone‑based drugs for obesity/NASH and thymosin‑β4 peptide therapeutics for tissue repair | — |
Top 7 Biopharma Outsourcing companies in South Korea
#1
Series C · Cheongju-si, Chungcheongbuk-do · founded 2015 · 186 employees$34.8Mraised▾
CDMO focused on manufacturing of biologics and commercialization services
- Mar 2023Series C$34.8M
#2
Series A · Pohang si, North Gyeongsang Province · founded 2000$3.2Mraised▾
Developer of biomaterials and pharmaceuticals intended to balance the immune system in a healthy way. The company provides contract research services for new drug development as well as conducting collaborative research products with various other domestic and foreign universities, research labs, and institutions, enabling patients to cure diseases, such as atopy, asthma, dry eye disease, and inflammatory bowel disease.
#3
Seed · Hwaseong, Gyeonggi do · founded 2022—raised▾
Provider of biopharma outsourcing services. It provides specialized pharmaceutical delivery services for biological products by implementing measures such as locking facilities and recording entry and exit logs.
- Jun 2024Seed—
#4
Series B · Goyang, Gyeonggi do · founded 2018 · 14 employees—raised▾
Operator of a drug development and research firm designed to verify the efficacy of new drug candidates or developed drugs and improve the lives of patients suffering from chronic conditions. The company engages in providing contract-based research services to validate the data of drug efficacy to fill the unmet needs of pharmaceutical companies and also develops drug candidates with special emphasis on reopening cortical plasticity, enabling clients to develop new drugs and help in targeting CNS conditions, including Alzheimer's Disease (AD), PTSD (Post Traumatic Stress Disorder), addiction, amblyopia, and stroke.
- 2022Series B—
- 2020Series A—
#5
Funding Raised · Cheongju-si, Chungcheongbuk-do · founded 2016—raised▾
Provider of preclinical studies services
- Jul 2019Grant (prize money)—
#6
Public · Siheung si, Gyeonggi do · founded 2008 · 639 employees—raised▾
CDMO providing oligonucleotide, mRNA, and small molecule services. This company offers contract development and manufacturing services across various therapeutic modalities. Their services encompass research and development, encompassing virtual and global R&D capabilities. They also provide analytical testing and quality control services. The company supports clients throughout the entire drug development lifecycle, from early-stage research to commercial manufacturing.
#7
Public · Seongnam-si, Gyeonggi-do · founded 2003—raised▾
Corestem is a company specializing in the development and production of stem cell-based therapies for incurable diseases. The company's only commercialized product Neuronata-R injection is an autologous bone marrow mesenchymal stem cell (autologous BM-MSC) therapy for Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease). The company's other candidates, CS20AT04 (for Lupus) and CS10BR05 (for multiple system atrophy) are in IND stage while their candidate CS30MS02 (for osteoarthritis) is in preclinical stage.
- Aug 2013Series A—
- Dec 2012Series A—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Biopharma Outsourcing coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in South Korea
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 885 South Korea-affiliated papers.
- Ministry of Agriculture118
- Ministry of Education70
- Seoul National University53
- Yonsei University44
- Korea University36
- Gene2→26
- Genome1→10
- Transcription factor1→9
- Genome editing1→6
- Transformation (genetics)1→6
- Antimicrobial1→23
- Apoptosis1→12
- Cell culture2→10
- Cytotoxicity2→8
- Gene knockdown1→7
- Human health2→11
- Health benefits1→6
- Antibiotic resistance1→4
- Toxicity2→4
Where biotechnology is researched across South Korea
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in South Korea
South Korea biotechnology patent filing is accelerating — 58,964 filings from 8,000 assignees (2016–2025), led by CJ Cheiljedang, UNIV Korea RES & BUS Found, Samsung; annual filings 4052→6791.
- CJ Cheiljedang6608
- UNIV Korea RES & BUS Found1920
- Samsung1764
- Korea Advanced INST SCI & TECH1756
- Seoul NAT UNIV R&DB Foundation1752
- Korea RES INST Of Bioscience1535
- Hanmi Pharm IND1198
- Korea RES INST Bioscience & Biot1009
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.